WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION
Sunnyvale, California ̶ October 3, 2023 ̶ Willow Biosciences Inc., (“Willow”) (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient (“API”) through precision fermentation. Through the partnership, SUANFARMA will have access to Willow’s […]
WILLOW BIOSCIENCES ANNOUNCES COMPANY INSIDER LED CONVERTIBLE DEBENTURE FINANCING
Calgary, Alberta – September 12, 2023 – Willow Biosciences Inc.(“Willow” or the “Company“) (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announcean offering of convertible debenture units of the Company (the “Debenture Units“), on a non-brokered private placement basis, for aggregate proceeds of […]
WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA
Company’s BioOxi™ Platform solves for selective C-H hydroxylation, one of the “Holy Grails” of chemistry BioOxi is broadly applicable to manufacturing of intermediates and active pharmaceutical ingredients, particularly for steroid applications SUNNYVALE, California – September 6, 2023 – Willow Biosciences Inc.(“Willow“) (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, […]
WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT SIGNFICANTLY REDUCED COST
Company’s BioOxi™-based process reduces number of steps and associated costs of corticosteroids manufacturing by up to two-thirds Sunnyvale, California – August 30, 2023 – Willow Biosciences Inc.(“Willow“) (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, announces the development of a process to produce corticosteroids […]
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM
Announces commercial focus on BioOxiTM bio-oxidation platform as part of targeted alignment on nearer-term and larger revenue opportunities Reduces number of board members as part of geographic transition as a San Francisco Bay Area-based biotech company SUNNYVALE, California – August 24, 2023 – Willow Biosciences Inc. (“Willow“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing […]
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Sunnyvale, California – August 21, 2023 – Willow Biosciences Inc. (“Willow“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, today announced a collaboration with a Nasdaq-listed biopharma company to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients (APIs). Willow’s collaboration partner […]